FY2025 EPS Estimates for TSE:HLS Raised by Clarus Securities

Key Points

• Clarus Securities has increased its FY2025 earnings estimate for HLS Therapeutics from ($0.45) to ($0.40) per share, while also projecting FY2026 earnings at ($0.18) EPS.
• Raymond James Financial upgraded HLS Therapeutics from a "hold" to a "moderate buy" rating and raised the price target from C$5.00 to C$6.00.
• The consensus rating for HLS Therapeutics remains a "Hold" with an average target price of C$5.00, reflecting cautious investor sentiment.

HLS Therapeutics Inc. (TSE:HLS - Free Report) - Clarus Securities raised their FY2025 earnings per share estimates for HLS Therapeutics in a report issued on Thursday, August 21st. Clarus Securities analyst G. Ulybyshev now anticipates that the company will earn ($0.40) per share for the year, up from their previous forecast of ($0.45). The consensus estimate for HLS Therapeutics' current full-year earnings is ($0.12) per share. Clarus Securities also issued estimates for HLS Therapeutics' FY2026 earnings at ($0.18) EPS.

Separately, Raymond James Financial upgraded HLS Therapeutics from a "hold" rating to a "moderate buy" rating and increased their target price for the stock from C$5.00 to C$6.00 in a research report on Thursday, August 21st. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of C$5.00.

HLS Therapeutics Stock Performance

Shares of TSE:HLS traded up C$0.01 during trading on Monday, hitting C$5.36. 5,221 shares of the company were exchanged, compared to its average volume of 12,445. The company has a market cap of C$168.27 million, a PE ratio of -11.17 and a beta of 0.68. The stock has a 50 day moving average of C$4.99 and a 200 day moving average of C$4.64. HLS Therapeutics has a 52-week low of C$3.00 and a 52-week high of C$5.48. The company has a debt-to-equity ratio of 86.50, a current ratio of 1.56 and a quick ratio of 1.01.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.